Given the paragraph for Cohort A match the table, it definitely looks like the table doesn't have the correct Cohort B data. Even more strange IMU hasn't release an update for Azer-Cel to include another CR unless there's an announcement tomorrow......possibly another trade by Precision again given the volume increase in the last few days like last time???
"Twelve patients were treated; 7 (58%) had ³4 prior therapies, and all received prior CD19 CAR T. Adverse events were generally mild, with no Grade ³3 cytokine release syndrome (CRS) or GvHD. Serious Grade ³3 events occurred in 2 patients: immune effector cell-associated neurotoxicity (ICANS), disseminated intravascular coagulation, cytomegalovirus reactivation, and retroperitoneal hematoma in 1 patient, resulting in death; and febrile neutropenia in the other patient. Five (42%) patients responded to azer-cel, with 2 (17%) achieving complete response (CR) (Table 1)."
IMU Price at posting:
3.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)